Advertisement

Picture [iito] Made Without Love 650x80px
Organisation › Details

Aelis Farma (FR)

AELIS FARMA is a clinical-stage biotechnology company founded in 2014 as a spin-off of the Neurocentre Magendie in Bordeaux, one of the major Neuroscience institute of INSERM (the French National Institute of Health and Medical Research). AELIS FARMA’s mission is to develop a new pharmacological class, the Signaling Specific inhibitors of the CB1 receptor (CB1-SSI) that have been discovered by the research team of Dr. Pier Vincenzo Piazza, the Company’s CEO, during his tenure as director of the Magendie Institute. For this discovery Dr. Piazza has been awarded the Grand Prix of INSERM and the Gran Prix of Neurology of the French Academy of Science, that are among the most prestigious French scientific award. CB1-SSi have potential application for the treatment of numerous disorders. The Company is currently developing two first-in-class drug candidates: AEF0117, and AEF0217. AEF0117, which targets cannabis related disorders (addictions and psychosis), is currently being studied in a Phase II trial in cannabis addicts performed at Columbia University (NY, USA). The effects of AEF0117 on cannabisinduced psychotic symptomatology will also be evaluated in an exploratory study in 2020. AEF0217, which is being developed for the treatment of cognitive impairments, will enter Phase I clinical trials in 2020 and will be tested as a therapy of cognitive deficits in Down syndrome. AELIS FARMA has 12 staff members, headquarters at the Neurocentre Magendie in Bordeaux and has received financial support from the Nouvelle-Aquitaine region, Inserm Transfert Initiative, Bpifrance, ACI, NACO and Aelis Innovation regional funds. *

 

Period Start 2014-01-01 established (s-off)
  Predecessor Neurocentre Magendie (Bordeaux, INSERM)
Products Industry AEF0117 (Aelis Farma)
  Industry 2 AEF0217 (Aelis Farma)
Person Person Piazza, Pier Vincenzo (Aelis Farma 201912 CEO + INSERM Neurocentre Magendie Bordeaux)
     
Region Region Bordeaux
  Country France
  Street 146 Rue Léo Saignat
Neurocentre Magendie
  City 33077 Bordeaux
  Tel +33-5-5757-3770
    Address record changed: 2020-12-02
     
Basic data Employees B: 11 to 50 (2019-12-13)
     
    * Document for �About Section�: Aelis Farma. (12/13/19). "Press Release: Aelis Farma Raises €11 Million to Accelerate the Clinical Development of a Paradigm-Shifting New Class of Drugs for Treating Cannabis Addiction and Cognitive Disorders". Bordeaux.
     
   
Record changed: 2019-12-16

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Aelis Farma (FR)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top